Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.46 |
| ▸ | ESR1 | P03372 | 11/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31500937 | 0.79 | APP (0.57) | APPESR1ESR2MEN1POLB | |
| SCHEMBL1104938 | 0.73 | APP (0.44) | APPESR1ESR2MIFPFKFB3 | |
| SCHEMBL30267413 | 0.72 | MIF (0.60) | MIFPFKFB3MEN1NPC1RAB9A | |
| SCHEMBL591197 | 0.72 | MIF (0.60) | MIFPFKFB3MEN1NPC1RAB9A | |
| SCHEMBL29814693 | 0.71 | APP (0.59) | APPESR1ESR2MEN1NPC1 | |
| SCHEMBL12984911 | 0.69 | APP (0.57) | APPESR1ESR2MEN1POLB | |
| SCHEMBL17716521 | 0.69 | APP (0.57) | APPESR1ESR2MEN1NPC1 | |
| SCHEMBL29352834 | 0.69 | USP2 (0.56) | MEN1POLBKMT2A | |
| SCHEMBL6693395 | 0.69 | USP2 (0.56) | MEN1POLBKMT2A | |
| SCHEMBL3728723 | 0.67 | USP2 (0.57) | ESR1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153828-B2 | Optical molecular sensors for cytochrome P450 activity | Life Technologies Corporation (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153828-B2 | Optical molecular sensors for cytochrome P450 activity | Life Technologies Corporation (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100105095-A1 | Optical Molecular Sensors for Cytochrome P450 Activity | Life Technologies Corporation (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105095-A1 | Optical Molecular Sensors for Cytochrome P450 Activity | Life Technologies Corporation (US) | 2010-04-29 | — | — | US | disclosed |
| US-20080125586-A1 | Optical molecular sensors for cytochrome P450 activity | INVITROGEN CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125586-A1 | Optical molecular sensors for cytochrome P450 activity | INVITROGEN CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20070072256-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | INVITROGEN CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072256-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | INVITROGEN CORPORATION | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105095-A1 | Optical Molecular Sensors for Cytochrome P450 Activity | CYP2J2, CYP1A2, CYP2B6 | APP 3233/4885ESR1 321/4885ESR2 146/4885 |
| US-20080125586-A1 | Optical molecular sensors for cytochrome P450 activity | CYP2J2, CYP1A2, CYP2B6 | APP 3233/4885ESR1 321/4885ESR2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.